IL6 and type 2 diabetes mellitus: In contrast, chronic low-grade IL-6 elevation in T2D engages the JAK/STAT3–SOCS3 pathway, driving SOCS3 overexpression, IRS-1 inhibition and downstream PI3K/AKT suppression [52,168,169].